International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Reviewer Referral Program
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
Conferences Published ↓
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 6 Issue 5
September-October 2024
Indexing Partners
Potential of Trimetazidine in Protecting the Myocardium on Coronary Artery Bypass Grafting Surgery: A Systematic Review and Meta-Analysis
Author(s) | Muhammad Sabri, Annisa Tria Fadilla, Hariadi Hatta, Brilliant, Moch Habib |
---|---|
Country | Indonesia |
Abstract | Aims: Increased biochemicals such as Troponin T, CKMB, and CK from myocardial injury are side effects of CABG. Trimetazidine is an anti-ischemic agent that can also have a cardioprotective. We conducted a systematic review and meta-analysis to analyse the role of trimetazidine therapy on postoperative myocardial preservation in CABG. Methods: The research instrument used was RCT test articles that have been published in the PubMed, Cochrane, and Google Scholar databases in 2013 and 2023. We were classified into two group analyses based on sampling time (at least ≤12 or >12 hours after CABG). Results: Five RCTs were finally included in the meta-analysis. Significant differences in TnT, CK-MB, and CK were found between trimetazidine-treated CABG patients and control CABG patients (p < 00001) in the subgroup examinations conducted ≤12 and >12 post-CABG, indicating significantly lower postoperative TnT, CK-MB, and CK levels in trimetazidine-treated CABG patients compared with control CABG patients. Conclusion: Myocardial preservation of CABG by comparing the effects of trimetazidine and placebo by assessing several levels of myocardial damage such as TnT, CK-MB, and CK was significantly lower in CABG patients treated with trimetazidine compared with control CABG patients. |
Keywords | Trimetazidine, Protecting the Myocardium, CABG, Systematic Review and Meta-Analysis |
Field | Medical / Pharmacy |
Published In | Volume 5, Issue 6, November-December 2023 |
Published On | 2023-11-20 |
Cite This | Potential of Trimetazidine in Protecting the Myocardium on Coronary Artery Bypass Grafting Surgery: A Systematic Review and Meta-Analysis - Muhammad Sabri, Annisa Tria Fadilla, Hariadi Hatta, Brilliant, Moch Habib - IJFMR Volume 5, Issue 6, November-December 2023. DOI 10.36948/ijfmr.2023.v05i06.9145 |
DOI | https://doi.org/10.36948/ijfmr.2023.v05i06.9145 |
Short DOI | https://doi.org/gs5mfv |
Share this
E-ISSN 2582-2160
doi
CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.